CBD for Anxiety: Current Evidence and Recommendations
Based on current evidence, CBD cannot be recommended as a first-line treatment for anxiety disorders, though it may have a role as adjunctive therapy in treatment-resistant cases, particularly for physical symptoms of anxiety rather than cognitive symptoms like worry.
Evidence Quality and Limitations
The available evidence for CBD in anxiety treatment is insufficient to support routine clinical use. While CBD shows some promise, the data comes primarily from small studies with significant methodological limitations 1, 2. The American College of Physicians notes that cannabis remains a Schedule I controlled substance federally, with CBD products largely unregulated outside of FDA-approved formulations 1.
FDA-Approved vs. Non-Approved Products
Only one CBD product has FDA approval: Epidiolex, which is indicated exclusively for specific epilepsy syndromes (Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex), not for anxiety disorders 1. All other CBD products marketed for anxiety lack FDA oversight for purity, potency, or safety.
Clinical Evidence for Anxiety
What Works (Limited Evidence)
- Physical anxiety symptoms: One study showed 300 mg oral CBD reduced physical anxiety symptoms over 2 weeks, but had no effect on cognitive symptoms like worry 3
- Treatment-resistant anxiety in youth: An open-label trial in young people (ages 12-25) with treatment-resistant anxiety showed 42.6% reduction in anxiety severity using CBD 200-800 mg/day over 12 weeks 4
- Social anxiety disorder: Some evidence supports acute dosing for social anxiety, though data remain limited 5
What Doesn't Work
- Cognitive anxiety symptoms (worry): CBD at 300 mg showed no effect on worry severity after either acute or repeated dosing 3
- Acute single doses: No consistent benefit demonstrated for immediate anxiety relief 3
- THC-containing products: Evidence is ambiguous, with anxiety exacerbation in some individuals 6, 7
Dosing Considerations (When Used)
Based on available research, if CBD is considered for treatment-resistant anxiety:
- Starting dose: 200-300 mg/day orally
- Titration: Increase gradually based on response and tolerability
- Target range: 300-800 mg/day (most studies used this range)
- Formulation: Oral capsules or oils (sublingual absorption)
- Time to assessment: Evaluate benefit within 3 months 8, 4
Critical caveat: Doses below 300 mg/day showed minimal to no effect in controlled trials 2, 3.
Safety Monitoring Requirements
Hepatotoxicity Risk
Baseline and ongoing liver function monitoring is essential 2:
- Check AST/ALT at baseline
- Recheck at 6 weeks post-initiation
- Follow-up at 3 months
- Monitor more frequently if combined with valproate or other hepatotoxic medications
Risk profile: Meta-analysis showed 7% incidence of elevated liver enzymes and 3% drug-induced liver injury, with no cases reported at total daily doses <300 mg 2. However, 13% of patients on FDA-approved CBD (Epidiolex) reached three times the upper limit of normal for transaminases 2.
Common Adverse Effects
Expect and counsel patients about 2, 4:
- Sedation and somnolence (most common)
- Fatigue
- Dizziness and confusion
- Dry mouth
- Diarrhea and nausea
- Decreased appetite
Serious but less common: Tachycardia, orthostatic hypotension, severe confusion, paranoia 2.
Drug Interactions
CBD inhibits multiple cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19, others) 2:
- Very high risk: Warfarin (monitor INR closely)
- High risk: Buprenorphine, tacrolimus
- Moderate concern: Any medication metabolized by CYP450 enzymes
Special Populations to Avoid
Do not use CBD in 1:
- Pregnant or breastfeeding individuals (FDA/Surgeon General warning)
- Adolescents under 18 (risk of neurodevelopmental effects, psychosis, depression)
- Patients with active substance use disorders
- Those operating vehicles or machinery (impairs reaction time)
Clinical Algorithm
Step 1: Ensure patient has failed adequate trials of:
- First-line SSRIs/SNRIs
- Evidence-based psychotherapy (CBT, exposure therapy)
Step 2: If considering CBD for treatment-resistant anxiety:
- Obtain baseline AST/ALT
- Review all medications for interaction potential
- Screen for pregnancy, substance use, psychiatric comorbidities
- Counsel on unregulated nature of non-FDA products
Step 3: If proceeding:
- Start 200-300 mg/day oral CBD
- Recheck LFTs at 6 weeks
- Assess response at 12 weeks
- Target physical anxiety symptoms, not cognitive worry
Step 4: If no benefit at 12 weeks, discontinue and pursue alternative treatments
Critical Pitfalls
Product variability: Over-the-counter CBD products are unregulated and may contain variable CBD concentrations, THC contamination, or harmful additives 1
Dose confusion: Many commercial products contain 25-50 mg doses, which are below the threshold shown to have any effect in clinical trials 3, 5
Wrong expectations: CBD does not address cognitive anxiety symptoms (worry, rumination) and should not be positioned as treating the core features of generalized anxiety disorder 3
THC confusion: Products containing THC may worsen anxiety and carry additional risks including psychosis, cannabis use disorder, and cognitive impairment 1, 2, 7
Regulatory status: Prescribing or recommending CBD for anxiety occurs outside FDA-approved indications and may have medicolegal implications 1
Bottom Line
The evidence does not support CBD as standard treatment for anxiety disorders. If used at all, CBD should be reserved for treatment-resistant cases where conventional therapies have failed, with careful monitoring for hepatotoxicity, realistic expectations about modest benefits limited to physical symptoms, and awareness of the unregulated nature of most available products 4, 6, 9, 5.